Literature DB >> 27823608

Insulin: Making Sense of Current Options.

Alissa R Segal1, Tejaswi Vootla2, Richard S Beaser2.   

Abstract

Newer insulin products have advanced the evolution of insulin replacement options to more accurately mimic natural insulin action. There are new, modified, and concentrated insulins; administration devices calibrated for both increased concentrations and administration accuracy to improve adherence and safety; and inhaled insulin. There are new combinations of longer-acting basal insulin and rapid-acting insulin or glucagon like protein-1 receptor agonists. Existing insulin replacement designs and methods can be updated using these tools to improve efficacy and safety. Individualized decisions to use them should be based on patient physiologic needs, self-care ability, comorbidities, and cost considerations.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Afrezza; Basaglar; Glargine U-300; Insulin; Insulin degludec; Insulin therapy; Lispro U-200; Regular U-500

Mesh:

Substances:

Year:  2016        PMID: 27823608     DOI: 10.1016/j.ecl.2016.06.009

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  4 in total

Review 1.  Oral Insulin Delivery in a Physiologic Context: Review.

Authors:  Ehud Arbit; Miriam Kidron
Journal:  J Diabetes Sci Technol       Date:  2017-02-02

2.  An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein.

Authors:  Michael D Glidden; Khadijah Aldabbagh; Nelson B Phillips; Kelley Carr; Yen-Shan Chen; Jonathan Whittaker; Manijeh Phillips; Nalinda P Wickramasinghe; Nischay Rege; Mamuni Swain; Yi Peng; Yanwu Yang; Michael C Lawrence; Vivien C Yee; Faramarz Ismail-Beigi; Michael A Weiss
Journal:  J Biol Chem       Date:  2017-11-07       Impact factor: 5.157

3.  Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.

Authors:  Karl-Michael Derwahl; Timothy S Bailey; Karin Wernicke-Panten; Lin Ping; Suzanne Pierre
Journal:  Diabetes Technol Ther       Date:  2017-12-12       Impact factor: 6.118

Review 4.  Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement.

Authors:  Francesco Giorgino; Alfred Penfornis; Valeria Pechtner; Raffaella Gentilella; Antonella Corcos
Journal:  Patient Prefer Adherence       Date:  2018-05-07       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.